OMEICOS Therapeutics GmbH - News

OMEICOS Appoints Dr. Ulrich Dauer as Chief Executive Officer

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced the appointment of Dr. Ulrich Dauer as Chief Executive Officer, effective April 13, 2015.

Page 2 of 2